Literature DB >> 20004987

Initial Q waves and outcome after reperfusion therapy in patients with ST elevation acute myocardial infarction: a systematic review.

Cheuk-Kit Wong1, Peter Herbison.   

Abstract

BACKGROUND: Patients with ST elevation acute myocardial infarction (STEMI) have different outcome depending on the reperfusion strategy.
METHODS: To discern if the presence of initial Q waves in the infarct leads is a useful prognostic parameter in STEMI patients within 6 h of symptom onset treated by different reperfusion strategies (fibrinolysis, fibrinolysis followed by percutaneous coronary intervention [PCI], and primary PCI) we performed a systematic review on outcome comparing patients with and without initial Q waves.
RESULTS: The relative risks for those with Q waves were significantly raised for both mortality and the composite outcome of mortality, congestive heart failure or cardiogenic shock, and at both 30-day and 90-day time points. The relative risk for mortality varied from 2.18 (95% CI 1.32-3.61) at 30 days to 2.54 (95% CI 1.87-3.44) at 90 days. The relative risk for composite outcome was 2.28 (95% CI 1.71-3.04) at 30 days and 2.25 (95% CI 1.81-2.80) at 90 days.
CONCLUSION: The presence of initial Q waves is a relatively robust parameter to stratify outcome regardless of the reperfusion methods.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20004987     DOI: 10.1016/j.ijcard.2009.11.013

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study.

Authors:  Ioanna Kosmidou; Björn Redfors; Aaron Crowley; Bernard Gersh; Shmuel Chen; José M Dizon; Monica Embacher; Roxana Mehran; Ori Ben-Yehuda; Gary S Mintz; Gregg W Stone
Journal:  Clin Cardiol       Date:  2017-07-11       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.